Literature DB >> 28472542

Programmed cell death ligand 1 as a biomarker in head and neck cancer.

Sara I Pai1, William C Faquin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28472542      PMCID： PMC5690557          DOI： 10.1002/cncy.21872

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN： 1934-662X            Impact factor:   5.284


× No keyword cloud information.
  31 in total

1.  BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.

Authors:  Trevor E Angell; Melissa G Lechner; Julie K Jang; Adrian J Correa; Jonathan S LoPresti; Alan L Epstein
Journal:  Thyroid       Date:  2014-07-15       Impact factor: 6.568

2.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Authors:  Tanguy Y Seiwert; Barbara Burtness; Ranee Mehra; Jared Weiss; Raanan Berger; Joseph Paul Eder; Karl Heath; Terrill McClanahan; Jared Lunceford; Christine Gause; Jonathan D Cheng; Laura Q Chow
Journal:  Lancet Oncol       Date:  2016-05-27       Impact factor: 41.316

3.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

6.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

Authors:  Scott E Strome; Haidong Dong; Hideto Tamura; Stephen G Voss; Dallas B Flies; Koji Tamada; Diva Salomao; John Cheville; Fumiya Hirano; Wei Lin; Jan L Kasperbauer; Karla V Ballman; Lieping Chen
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

7.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

8.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Authors:  Manish J Butte; Mary E Keir; Theresa B Phamduy; Arlene H Sharpe; Gordon J Freeman
Journal:  Immunity       Date:  2007-07-12       Impact factor: 31.745

9.  Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.

Authors:  Joao Paulo Oliveira-Costa; Alex Fiorini de Carvalho; da Giorgia Gobbi da Silveira; Peter Amaya; Yongqi Wu; Kyoung-Joo Jenny Park; Mabel Pinilla Gigliola; Maryam Lustberg; Marcilei Eliza Cavicchioli Buim; Elisa Napolitano Ferreira; Luiz Paulo Kowalski; Jeffrey J Chalmers; Fernando Augusto Soares; Dirce Maria Carraro; Alfredo Ribeiro-Silva
Journal:  Oncotarget       Date:  2015-08-28

10.  Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.

Authors:  Subrata Chowdhury; Joe Veyhl; Fatima Jessa; Olena Polyakova; Ahmed Alenzi; Christina MacMillan; Ranju Ralhan; Paul G Walfish
Journal:  Oncotarget       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.